Question to the Department of Health and Social Care:

To ask Her Majesty's Government what percentage of eligible patients have received doses of COVID-19 antiviral therapies within the five day guidelines set out by Joint Committee on Vaccination and Immunisation.

Clinical access policies specify that the oral antiviral treatments molnupiravir and nirmatrelvir+ritonavir must be administered within five days of the patient starting to experience symptoms. Over 95% of eligible non-hospitalised patients who have received an antiviral treatment to date were treated within five days from the onset of symptoms. However, the antiviral infusion remdesivir is suitable to be administered within seven days of the patient becoming symptomatic.